Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Accounts Payables: 2015-2025

Historic Accounts Payables for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Sep 2025 value amounting to $13.8 million.

  • Syndax Pharmaceuticals' Accounts Payables rose 182.28% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year increase of 182.28%. This contributed to the annual value of $11.6 million for FY2024, which is 16.72% up from last year.
  • As of Q3 2025, Syndax Pharmaceuticals' Accounts Payables stood at $13.8 million, which was down 20.33% from $17.4 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' Accounts Payables' 5-year high stood at $17.4 million during Q2 2025, with a 5-year trough of $3.6 million in Q2 2021.
  • Its 3-year average for Accounts Payables is $10.3 million, with a median of $10.0 million in 2025.
  • In the last 5 years, Syndax Pharmaceuticals' Accounts Payables dropped by 27.44% in 2021 and then spiked by 182.28% in 2025.
  • Syndax Pharmaceuticals' Accounts Payables (Quarterly) stood at $5.7 million in 2021, then dropped by 23.27% to $4.3 million in 2022, then skyrocketed by 128.99% to $10.0 million in 2023, then climbed by 16.72% to $11.6 million in 2024, then spiked by 182.28% to $13.8 million in 2025.
  • Its last three reported values are $13.8 million in Q3 2025, $17.4 million for Q2 2025, and $10.0 million during Q1 2025.